Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2312051 | 1.00 | ALDH1A1 (0.35) | ALDH1A1KDM4EALOX15HSD17B10 | |
| SCHEMBL6058815 | 0.98 | ALDH1A1 (0.34) | ALDH1A1KDM4EALOX15HSD17B10 | |
| SCHEMBL3095106 | 0.91 | KDM4E (0.39) | ALDH1A1KDM4E | |
| SCHEMBL6811544 | 0.84 | KDM4E (0.35) | ALDH1A1KDM4E | |
| SCHEMBL1289407 | 0.84 | ALDH1A1 (0.32) | ALDH1A1ALOX15 | |
| SCHEMBL11825898 | 0.82 | KDM4E (0.33) | ALDH1A1KDM4E | |
| SCHEMBL2964675 | 0.81 | ALDH1A1 (0.32) | ALDH1A1ALOX15HSD17B10 | |
| SCHEMBL2964678 | 0.81 | ALDH1A1 (0.32) | ALDH1A1ALOX15HSD17B10 | |
| SCHEMBL5693065 | 0.81 | ALDH1A1 (0.36) | ALDH1A1ALOX15HSD17B10 | |
| SCHEMBL9988092 | 0.81 | ALDH1A1 (0.32) | ALDH1A1ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961424-A1 | ADMINISTRATION OF AN ANTI-GCC ANTIBODY-DRUG CONJUGATE AND A DNA DAMAGING AGENT IN THE TREATMENT OF CANCER | Millennium Pharmaceuticals, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2841103-A1 | DR5 LIGAND DRUG CONJUGATES | Seattle Genetics, Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| WO-2014134311-A1 | ADMINISTRATION OF AN ANTI-GCC ANTIBODY-DRUG CONJUGATE AND A DNA DAMAGING AGENT IN THE TREATMENT OF CANCER | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2013163229-A1 | DR5 LIGAND DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2013-10-31 | — | — | WO | disclosed |
| EP-2629801-A2 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | Seattle Genetics, Inc. (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8389752-B2 | Preparation of alicyclic diepoxides | Peomerus LLC (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2533804-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | Agensys, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2012054748-A2 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEATTLE GENETICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-8115043-B2 | Method for producing cyclic olefin compound | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| WO-2011097627-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| EP-2350062-A1 | PREPARATION OF ALICYCLIC DIEPOXIDES | Sumitomo Bakelite Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20100094030-A1 | Preparation Of Alicyclic Diepoxides | PROMERUS LLC (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010042939-A1 | PREPARATION OF ALICYCLIC DIEPOXIDES | PROMERUS LLC (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20090062580-A1 | Method for Producing Cyclic Olefin Compound | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-2014634-A1 | PROCESS FOR PRODUCTION OF CYCLIC OLEFINS | Daicel Chemical Industries, Ltd. (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062580-A1 | Method for Producing Cyclic Olefin Compound | ADH1C, ADH1A, DHCR24 | ALDH1A1 338/4885KDM4E 3346/4885ALOX15 358/4885 |
| US-20100094030-A1 | Preparation Of Alicyclic Diepoxides | MVD, DLD, DHPS | ALDH1A1 318/4885KDM4E 352/4885ALOX15 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.